Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2021

View Archived Issues

Researchers develop a nonhuman primate model of Parkinson's disease

SNS-101, an anti-VISTA antibody, potentiates anti-PD-1/PD-L1 antitumor immunity

GNE-502 shows promising efficacy in breast tumor xenograft model

ALTA-002, a Toll-like receptor agonist antibody conjugate with promising antitumor activity in vivo

Idorsia Pharmaceuticals patents CCR6 antagonists

Novartis synthesizes HIF-2alpha inhibitors

Perha Pharmaceuticals identifies CLK1 and/or CLK4 and/or DYRK1A inhibitors

A novel protein-engineered IL-12 shows efficacy without peripheral toxicity in animal models

Rhizen Pharmaceuticals synthesizes new PARP inhibitors

Preclinical Alzheimer's vaccine, therapy target soluble amyloid

RaQualia Pharma synthesizes new TRPV4 antagonists

Animal model recapitulates CCA susceptibility in progressive biliary injury and fibrosis

Novel CDK9 inhibitors as candidates for the treatment of acute myeloid leukemia

New fully synthetic antibiotic class shows broad activity against multidrug-resistant bacteria

Restoring cellular miR-127-3p inhibits herpesvirus-induced tumorigenesis in vitro and in vivo

Pridopidine has neuroprotective effects mediated by S1R in retinal ganglion cells of glaucoma models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...